Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is infantile fibrosarcoma?
Infantile fibrosarcoma is a soft-tissue tumor that occurs in the first months and years of life — most are found in babies under one year old, and many are present at birth. A sarcoma is a cancer of the body's connective tissues; infantile fibrosarcoma arises from fibrous tissue and usually appears as a firm, sometimes rapidly enlarging mass in an arm or leg (especially the hands, feet, lower legs, or forearms), and less often in the trunk or head and neck. The mass can grow quickly and look alarming, and the overlying skin may be stretched, red, or even ulcerated, which can raise fear of a very dangerous cancer. The reassuring reality is that infantile fibrosarcoma behaves far more gently than its appearance suggests: it rarely spreads to other parts of the body, and it is one of the most curable cancers of infancy. What makes it distinctive — and what has transformed its treatment — is that the great majority of these tumors are driven by a single specific gene fusion (most often an ETV6-NTRK3 fusion, involving the NTRK gene). Finding this fusion confirms the diagnosis and, crucially, identifies a target. Because the tumor depends on the abnormal NTRK signal, a class of targeted pills called NTRK inhibitors can switch off its growth signal and shrink it dramatically, often allowing doctors to avoid or greatly reduce intensive chemotherapy, large disfiguring surgery, and radiation in a very young child. The modern approach is therefore organized around doing the least harm to a developing baby while curing the tumor: complete surgical removal when it can be done without sacrificing function, targeted therapy or chemotherapy to shrink large tumors first so that surgery can be smaller (or sometimes avoided), and radiation reserved for the uncommon situations where it is truly needed. This represents a real success story in pediatric oncology — a once-worrisome tumor that is now usually cured with treatment tailored to spare the child.
The main types
Doctors group infantile fibrosarcoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Extremity infantile fibrosarcoma | The most common location — a firm, fast-growing mass on a hand, foot, lower leg, or forearm of a baby; highly curable, treated with surgery and, for large tumors, targeted therapy or chemotherapy to shrink it first. |
| Trunk / head-and-neck infantile fibrosarcoma | Less common locations where surgery may be more difficult; targeted therapy or chemotherapy is especially useful to shrink the tumor before any operation. |
| Congenital infantile fibrosarcoma | A tumor present at birth; the same favorable, highly curable disease, managed with the least intensive treatment that achieves cure. |
| Cellular congenital mesoblastic nephroma (kidney counterpart) | A closely related tumor of the infant kidney that shares the same NTRK gene fusion and favorable behavior; usually cured by surgery to remove the affected kidney. |
Staging, in plain terms
Infantile fibrosarcoma is not staged with the adult TNM system. Because it so rarely spreads, the assessment centers on practical questions rather than on a search for distant disease: how large is the tumor, where is it, and can it be removed without harming the baby's function or development. Doctors confirm the diagnosis and, just as importantly, look for the tumor's defining genetic feature — most carry an ETV6-NTRK3 gene fusion (an NTRK fusion), and finding it both proves the diagnosis and identifies the target for a specific pill. A modest amount of imaging checks the tumor's extent and, because spread is uncommon, a limited evaluation for any distant disease. The reason staging is so streamlined is the tumor's favorable behavior: unlike the aggressive sarcomas of older patients, infantile fibrosarcoma is locally growing but rarely metastatic, so the treatment conversation is much more about how to remove or shrink the tumor with the least harm to a developing infant than about controlling widespread cancer. In practice, the key questions are the tumor's size and location, whether it can be removed safely and with preserved function, whether it carries the NTRK fusion (which makes targeted therapy possible), and the baby's age and overall condition. These answers determine whether to operate first, to shrink the tumor first with targeted therapy or chemotherapy, or — rarely — to use radiation.
| Pediatric soft-tissue tumor assessment by size, location, and resectability (not adult TNM) — combined with testing for the characteristic NTRK (ETV6-NTRK3) gene fusion | What it generally means |
|---|---|
| Localized, completely removable | A tumor that can be fully removed with preserved function; often cured by surgery alone, with excellent outcomes. |
| Localized, large or awkwardly placed | A big tumor or one in a location where upfront surgery would be disfiguring; treated by shrinking it first with NTRK-targeted therapy or chemotherapy, then a smaller operation. |
| Localized, hard to remove | A tumor that can't be safely removed even after shrinking; managed with continued targeted therapy or chemotherapy, with radiation reserved for the uncommon cases that truly need it. |
| Spread (rare) | The uncommon situation where the tumor has spread; treated with systemic therapy — increasingly the NTRK-targeted pill — which can produce strong, durable responses. |
The standard of care
Infantile Fibrosarcoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery to remove the tumor (when function is preserved)
Complete removal that spares the limb's function is the goal and often cures the tumor by itself; surgeons avoid large, disfiguring operations in a baby when shrinking the tumor first can make a smaller operation possible.
NTRK-targeted therapy
A pill (an NTRK inhibitor such as larotrectinib or entrectinib) that switches off the tumor's driving gene signal; it can shrink the tumor dramatically, often allowing smaller surgery or sparing the child from chemotherapy and radiation.
Chemotherapy (to shrink large tumors)
A relatively gentle chemotherapy regimen can shrink a large tumor before surgery; it remains an option, though targeted therapy increasingly takes this role for NTRK-fusion tumors.
Molecular testing for the NTRK fusion
Testing the tumor for the ETV6-NTRK3 (NTRK) gene fusion confirms the diagnosis and identifies the target for the pill — a step that directly changes treatment toward the least-toxic option.
Radiation therapy (reserved for select cases)
Radiation is used sparingly in these very young children and reserved for the uncommon tumor that can't be controlled by surgery and drug therapy, because of its long-term effects on a developing body.
How radiation treatment works
Radiation therapy works by delivering focused beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. For most cancers it is a central treatment, but infantile fibrosarcoma is an important example of when the best use of radiation is to use very little of it. This tumor is highly curable, it rarely spreads, and it occurs in babies and toddlers whose bones, muscles, organs, and growth plates are actively developing and are especially vulnerable to the long-term effects of radiation. Combined with the fact that surgery and, increasingly, a targeted pill can usually cure the tumor, this means radiation is deliberately avoided in the great majority of children — sparing them the late effects on growth and development that radiation could cause. The modern strategy is built around that goal. When the tumor can be removed completely without harming function, surgery alone often cures it. When the tumor is large or awkwardly placed, doctors first shrink it — increasingly with an NTRK-targeted pill that switches off the tumor's driving gene signal, or with relatively gentle chemotherapy — so that a smaller, function-preserving operation becomes possible, again without radiation. Radiation is held in reserve for the uncommon tumor that cannot be controlled by surgery and drug therapy. In those select cases, the radiation is aimed tightly at the tumor area (involved-field) with the field and dose minimized, and proton beam therapy is favored when available because protons deposit their energy in the target and then stop, sparing the growing tissue beyond the tumor and lowering the risk of long-term side effects and second cancers. When protons are not available, intensity-modulated radiation shapes the beams tightly around the target to protect nearby growth plates and organs. In short, radiation's role in infantile fibrosarcoma is defined by restraint: powerful when truly needed, but used as little as possible because gentler, equally curative options come first.
The main ways radiation is delivered for infantile fibrosarcoma:
Radiation generally avoided in infants
Because infantile fibrosarcoma is highly curable with surgery and drug therapy, and because radiation can affect a baby's growing bones, muscles, and organs, radiation is deliberately avoided in most cases — a key principle of treating this favorable tumor.
Focal (involved-field) radiation when truly needed
In the uncommon situation where a tumor can't be controlled otherwise, radiation aimed tightly at the tumor area can help; the field and dose are minimized to protect surrounding developing tissue.
Proton beam radiation therapy
If radiation is required in a young child, protons deposit their energy in the target and stop, sparing growing tissue beyond the tumor and reducing long-term effects and second-cancer risk compared with standard X-ray radiation.
Intensity-modulated radiation (IMRT)
When protons are not available and radiation is needed, IMRT shapes photon beams tightly around the target to spare nearby growth plates, muscles, and organs as much as possible.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
NTRK-targeted pills transform treatment: Trials of NTRK inhibitors such as larotrectinib and entrectinib show dramatic, durable shrinkage of infantile fibrosarcomas carrying the ETV6-NTRK3 fusion, often allowing smaller surgery and sparing infants intensive chemotherapy and radiation.[1]
NTRK inhibitor trials in NTRK-fusion tumors
Function-preserving, de-intensified treatment: Pediatric studies confirm that because infantile fibrosarcoma rarely spreads and is highly curable, treatment can be de-escalated — favoring complete-but-conservative surgery and tumor shrinkage over aggressive operations, chemotherapy, and radiation.[2]
Pediatric soft-tissue sarcoma cooperative-group studies
ETV6-NTRK3 fusion confirms diagnosis: Identifying the characteristic ETV6-NTRK3 (NTRK) gene fusion distinguishes infantile fibrosarcoma from look-alike tumors and identifies the target for therapy — making molecular testing a routine, decisive step.[3]
Infantile fibrosarcoma molecular diagnostic studies
Common questions
The tumor grew fast and looks scary — is my baby in danger? It is completely understandable to be frightened, because infantile fibrosarcoma can grow quickly and the overlying skin may be stretched, red, or ulcerated. But this tumor behaves far more gently than it looks. It rarely spreads to other parts of the body, and it is one of the most curable cancers of infancy. With modern treatment — surgery when it can be done safely, and a targeted pill or gentle chemotherapy to shrink large tumors — the great majority of babies are cured. The alarming appearance does not reflect how this particular tumor actually behaves, and the care team will focus on curing it while protecting your child's growth and function.
What is the targeted pill, and why might it replace chemotherapy or radiation? Almost all infantile fibrosarcomas are driven by a single genetic change — most often an ETV6-NTRK3 fusion that produces an abnormal NTRK growth signal. A class of pills called NTRK inhibitors (such as larotrectinib and entrectinib) blocks that exact signal, and they can shrink these tumors dramatically. Because the pill targets the tumor's specific weakness, it can often shrink a large tumor enough to allow a smaller operation — or control the tumor outright — while sparing a baby the broader effects of chemotherapy and the long-term effects of radiation on a developing body. This is why molecular testing for the NTRK fusion is a routine first step, and why targeted therapy increasingly leads the treatment plan.
Will my child need radiation? Most likely not. Radiation is deliberately avoided in the great majority of children with infantile fibrosarcoma, because the tumor is highly curable with surgery and drug therapy and because radiation can affect a baby's growing bones, muscles, and organs. It is reserved for the uncommon tumor that can't be controlled by surgery and targeted therapy or chemotherapy. If radiation does become necessary, the team minimizes the area and dose and favors proton therapy when available to protect your child's developing tissue. The guiding principle is to cure the tumor with the least possible long-term effect on your child.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.